851,353 Shares in VYNE Therapeutics Inc. $VYNE Bought by Baker BROS. Advisors LP

Baker BROS. Advisors LP purchased a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 851,353 shares of the company’s stock, valued at approximately $285,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Velan Capital Investment Management LP bought a new position in shares of VYNE Therapeutics during the 2nd quarter worth about $50,000. Two Sigma Investments LP bought a new stake in shares of VYNE Therapeutics in the third quarter valued at about $74,000. Shay Capital LLC acquired a new stake in VYNE Therapeutics during the third quarter worth about $165,000. Boothbay Fund Management LLC acquired a new stake in VYNE Therapeutics during the second quarter worth about $176,000. Finally, TFG Asset Management GP Ltd bought a new position in VYNE Therapeutics during the second quarter valued at about $190,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

VYNE has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 2nd. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, VYNE Therapeutics currently has a consensus rating of “Reduce” and an average target price of $4.50.

VYNE Therapeutics Stock Up 0.7%

NASDAQ VYNE opened at $0.59 on Friday. VYNE Therapeutics Inc. has a twelve month low of $0.28 and a twelve month high of $1.99. The stock has a market cap of $19.70 million, a P/E ratio of -0.76 and a beta of 2.00. The company’s 50-day simple moving average is $0.58 and its 200 day simple moving average is $0.45.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.